Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 301 to 325 of 1147 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
402 increased inflammatory response (GO:0006954) corneal epithelial cell (CL:0000575) 777: Increase, Inflammation (corneal cells)
237 abnormal abnormal neuron morphology (MP:0002882) 851: Decrease of GABAergic interneurons
238 decreased secretion (GO:0046903) very-low-density lipoprotein (CHEBI:39027) 450: Decrease, Very low-density lipoprotein export capacity
239 decreased gene expression (GO:0010467) phosphoenolpyruvate carboxykinase, cytosolic [GTP] (PR:000012416) 216: Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)
240 increased fatty acid transport (GO:0015908) fatty acid (CHEBI:35366) 465: Increased, Fatty acid influx
241 increased gene expression (GO:0010467) low-density lipoprotein receptor (PR:000009744) 466: Up Regulation, LDLR (low density lipoprotein receptor)
242 increased receptor-mediated endocytosis (GO:0006898) low-density lipoprotein (CHEBI:39026) 467: Increased, LDL uptake
243 increased gene expression (GO:0010467) cytochrome P450 1A1 (PR:000006101) 80: Up Regulation, CYP1A1
244 decreased signaling (GO:0023052) nuclear receptor subfamily 1 group I member 3 (PR:000011398) 456: Suppression, Constitutive androstane receptor, NR1I3
245 increased signaling (GO:0023052) sterol regulatory element-binding protein 1 (PR:000015611) 457: Activation, SREBF1
246 increased triglyceride biosynthetic process (GO:0019432) triglyceride (CHEBI:17855) 454: Increased, Triglyceride formation
247 increased gene expression (GO:0010467) fatty acid synthase (PR:000007348) 463: Up Regulation, FAS
248 increased acetyl-CoA carboxylase activity (GO:0003989) acetyl-CoA carboxylase 1 (PR:000003596) 470: Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)
249 decreased signaling (GO:0023052) hepatocyte nuclear factor 4-alpha (PR:000008654) 461: Suppression, HNF4alpha
250 decreased signaling (GO:0023052) hepatocyte nuclear factor 3-beta (PR:000007603) 471: Inhibition, FoxA2
251 decreased gene expression (GO:0010467) carnitine O-palmitoyltransferase 1, liver isoform (PR:000005835) 472: Down Regulation, CPT1A
252 decreased gene expression (GO:0010467) hydroxymethylglutaryl-CoA synthase, mitochondrial (PR:000008638) 474: Down Regulation, HMGCS2
254 increased signaling (GO:0023052) nuclear factor erythroid 2-related factor 2 (PR:000011170) 478: Activation, NRF2
255 increased signaling (GO:0023052) bile acid receptor (PR:000011396) 479: Activation, NR1H4
344 decreased locomotion (GO:0040011) 635: Decreased, locomotion
376 increased preneoplasia (MP:0002009) abnormal cell mass (MP:0003902) 774: Increase, Preneoplastic foci (hepatocytes)
375 increased cell proliferation (GO:0008283) mitogenic signaling cell (CL:0000422) 716: Increase, cell proliferation (hepatocytes)
322 increased acetylcholine receptor activator activity (GO:0030549) Nicotinic acetylcholine receptor (FMA:61796) 663: Desensitization, Nicotinic acetylcholine receptor
379 increased pyruvate dehydrogenase activity (GO:0004738) pyruvate dehydrogenase [ubiquinone] (PR:000023575) 726: Increased, Induction of pyruvate dehydrogenase (PDH)
378 increased cellular respiration (GO:0045333) 769: Increase, Oxidative metabolism